LambdaVision Announces First Closing of Seed Round to Advance Artificial Retina Preclinical Studies for Retinal Eye Diseases
LambdaVision , an innovative biotech company developing a protein-based artificial retina to help patients regain sight lost to retinal degenerative diseases, announced it secured the first closing of its seed round being led by Aurelia Foundry Fund , a fund spun out of MIT.
- LambdaVision , an innovative biotech company developing a protein-based artificial retina to help patients regain sight lost to retinal degenerative diseases, announced it secured the first closing of its seed round being led by Aurelia Foundry Fund , a fund spun out of MIT.
- The round also includes investment from Boryung, a publicly listed Korean pharmaceutical company, and E2MC Ventures.
- While the preclinical studies are being conducted on Earth, LambdaVision is optimizing assembly of its artificial retina in low-Earth orbit.
- “We are proud to lead this seed round with LambdaVision and eager to support bringing a life-changing product to market,” said Ariel Ekblaw, GP, Aurelia Foundry Fund.